2,2-difluorobenzo[d][1,3]dioxole-5-carbaldehyde | 63124-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2,2-difluorobenzo[d][1,3]dioxole-5-carbaldehyde
• 英文别名: 2,2-dimethyl-benzo[1,3]dioxole-5-carbaldehyde；2,2-dimethylbenzo[d][1,3]dioxole-5-carbaldehyde；5-formyl-2,2-dimethyl-1,3-benzodioxole；2,2-dimethyl-1,3-benzodioxole-5-carbaldehyde
• CAS: 63124-55-0
• 化学式: C₁₀H₁₀O₃
• mdl: MFCD20488897
• 分子量: 178.188
• InChiKey: DVERJBIPBLPJQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  2-8°C，惰性气体

反应信息

• 作为反应物：
  描述：

  2,2-difluorobenzo[d][1,3]dioxole-5-carbaldehyde 在 甲酸 、 双氧水 作用下， 反应 20.0h， 以60%的产率得到2,2-dimethylbenzo[d][1,3]dioxol-5-ol
  参考文献：
  名称：

  Electron impact mass spectrometry of some benzodioxole derivatives of pharmacological interest, their synthons and synthetic intermediates

  摘要：

  AbstractThe mass spectrometric behaviour of two newly synthesized β‐blocking benzodioxole derivatives, their synthons and synthetic intermediates has been studied in detail with the aid of exact mass measurements, linked scans, collisionally activated decomposition mass analysed ion kinetic energy spectra and deuterium labelling experiments. A retrosynthetic process, leading to the original synthons, is described.

  DOI：

  10.1002/oms.1210191007
• 作为产物：
  描述：

  (2,2-dimethylbenzo[d][1,3]dioxol-5-yl)methanol 在 manganese(IV) oxide 作用下， 生成 2,2-difluorobenzo[d][1,3]dioxole-5-carbaldehyde
  参考文献：
  名称：

  Oxidative Intramolecular Phenolic Coupling Reaction Induced by a Hypervalent Iodine(III) Reagent:  Leading to Galanthamine-Type Amaryllidaceae Alkaloids

  摘要：

  By extending our oxidative phenol-coupling reactions using a hypervalent iodine(III) reagent, a versatile synthetic procedure for the galanthamine-type Amaryllidaceae alkaloids was accomplished. The first total synthesis of (+/-)-sanguinine and the total syntheses of (+/-)-galanthamine, (+/-)-narwedine, (+/-)-lycoramine, and (+/-)-norgalanthamine were also successfully carried out.

  DOI：

  10.1021/jo9807868

文献信息

• No-carrier-added (NCA) aryl [18F]fluorides via the nucleophilic aromatic substitution of electron-rich aromatic rings
  作者：Y.-S. Ding、C.-Y Shiue、J.S. Fowler、A.P. Wolf、A. Plenevaux

  DOI：10.1016/s0022-1139(00)80432-7

  日期：1990.6

  Nucleophilic aromatic substitution by [18F]fluoride ion has been demonstrated on rings containing electron donating groups in addition to the necessary electron withdrawing and leaving groups. The reaction of 18F− with a series of aromatic nitro aldehydes having protected hydroxyl substituents on the ring was studied. The reactivity of the aromatic ring towards nucleophilic substitution to give 18F-labeled

  除了必要的吸电子和离电子基团外，在含有给电子基团的环上还证明了[ 18 F]氟离子进行的亲核芳香族取代。反应18 ˚F -与一系列环上具有保护的羟基的取代基的芳族硝基醛进行了研究。芳环对亲核取代反应生成18 F-标记的芳族氟醛衍生物的反应性与反应中心的电子密度相关。报道了许多保护的羟基取代基的作用。13C-NMR被用作敏感的探针，用于改变环碳原子上电子分布的变化。放射化学产率与反应中心的ppm值相关。该方法学已应用于无载体添加（NCA）6- [ 18 F]氟-L-DOPA的合成。这种策略扩展到其他标记药物的合成似乎是有希望的。
• Indole, indazole and indoline derivatives as CETP inhibitors
  申请人：Conte-Mayweg Aurelia

  公开号：US20060030613A1

  公开（公告）日：2006-02-09

  The present invention relates to compounds of formula (I): wherein —X—Y—, R 1 to R 11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

  本发明涉及以下式(I)的化合物： 其中-X-Y-, R1至R11和n如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防通过CETP抑制剂介导的疾病是有用的。
• [EN] SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE<br/>[FR] COMPOSÉS D'HYDROXYÉTHYLAMINE SUBSTITUÉE EN TANT QUE MODULATEURS DE BÊTA-SÉCRÉTASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2009064418A1

  公开（公告）日：2009-05-22

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I) I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明涵盖了一类新化合物，用于调节Beta-分泌酶酶活性，治疗由Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一种实施方案中，这些化合物具有一般的化学式（I），其中R1、R2、R3、R4、R5、A1、A2、A3、A4、X和Z在此定义。该发明还包括将这些化合物用于制备药物组合物，用于治疗与beta-分泌酶蛋白活性相关的疾病和症状，如阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。该发明还包括进一步的化学式II实施方案，以及用于制备化合物I和II的中间体和工艺。
• Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use
  申请人：Graceffa Russell

  公开号：US20100120774A1

  公开（公告）日：2010-05-13

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明包括一类新化合物，用于调节Beta-分泌酶酶活性，治疗由Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一个实施例中，这些化合物具有一般的化学式I，其中R1、R2、R3、R4、R5、A1、A2、A3、A4、X和Z在此处被定义。该发明还包括将这些化合物用于治疗与beta-分泌酶蛋白活性相关的疾病和情况的药物组合物。这些疾病包括阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。该发明还包括化学式II的进一步实施例，以及有用于制备化学式I和II化合物的中间体和工艺。
• Cu-Catalyzed highly selective reductive functionalization of 1,3-diene using H₂O as a stoichiometric hydrogen atom donor
  作者：Qifan Li、Xiaoyang Jiao、Mimi Xing、Penglin Zhang、Qian Zhao、Chun Zhang

  DOI：10.1039/c9cc04011k

  日期：——

  diastereo-selective reductive reaction of terminal 1,3-diene with water and aldehyde has been developed. This chemistry afforded a product containing a terminal alkenyl group, which is a versatile kind of precursor for organic synthesis, with the scope for various substrates. The present reaction system could realize the catalytic transfer of hydrogen to diene using water as a stoichiometric H atom donor

  已经开发了铜催化的末端1,3-二烯与水和醛的高度区域和非对映选择性还原反应。这种化学作用提供了含有末端烯基的产物，该产物是用于有机合成的通用前体，具有适用于各种底物的范围。本反应体系可以用水为化学计量的H原子供体，实现氢向二烯的催化转移。在该转化中，使用了B 2 Pin 2（一种温和而实用的还原剂）作为介体。对照实验说明了该实用策略的反应途径。